S&P 500 index data: S&P 500 Copyright ©
All data supplied by Morningstar Real-Time Data. U.S. intraday real-time exchange quotes are sourced from BATS when available. End-of-day quotes for Nasdaq, NYSE, and Amex securities will appear 15 minutes after close. Graph times are Eastern Standard. © Copyright Morningstar, Inc .
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Morningstar Investing Classroom Rewards (earn as you learn and redeem for Morningstar merchandise)|
|P||Morningstar Fund Analyst Reports (full research on 2,000 funds and ETFs)|
|P||Morningstar Stock Analyst Reports (full research on 2,000 stocks)|
|P||Morningstar Stock and Fund Stewardship Grades|
|P||Portfolio Manager (advanced with 10 x-ray analyses, including guidance)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.
|Alkermes Presents Positive Results from Phase 2 Clinical Study of ALKS 5461 in Major Depressive Disorder at 53rd Annual NCDEU Meeting (2013/5/31)|
|Alkermes Presents Positive Results from Phase 1 Study of ALKS 3831 as a Broad Spectrum Treatment for Schizophrenia (2013/5/28)|
|Alkermes Announces Positive Results from Phase 2 Clinical Study of ALKS 5461 for Major Depressive Disorder (2013/4/17)|
|Alkermes Announces Data on ALKS 5461 and ALKS 3831 to Be Presented at 53rd Annual NCDEU Meeting (2013/5/22)|
|Alkermes plc Reports Third Quarter Fiscal 2013 Financial Results (2013/1/31)|
|Alkermes plc Reports Financial Results for Fiscal Year 2013 and Provides Financial Expectations (2013/5/23)|
|Alkermes Elects Nancy Wysenski to Board of Directors (2013/5/16)|
|Alkermes’ Corporate Presentation to be Webcast at Three Upcoming Conferences (2013/2/19)|
|Alkermes to Host Conference Call to Discuss Financial Results for Fiscal Year 2013 (2013/5/16)|
|Alkermes’ Corporate Presentation to be Webcast at Two Upcoming Conferences (2013/2/5)|
Click above to view more mutual fund data and stats for alks - Alkermes PLC.